Back to Main

GlobeImmune Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Overallotment Option


LOUISVILLE, Colo., July 8, 2014 (GLOBE NEWSWIRE) -- GlobeImmune, Inc. (Nasdaq:GBIM), today announced the closing of its previously announced initial public offering of 1,725,000 shares of its common stock at a price to the public of $10.00 per share, which includes 225,000 shares of common stock sold pursuant to the full exercise of the underwriter's overallotment option. The gross proceeds to GlobeImmune from the initial public offering were $17,250,000, before deducting underwriting discounts and commissions and other offering expenses. Shares of GlobeImmune, Inc. trade on the NASDAQ Capital Market under the ticker symbol "GBIM."

Aegis Capital Corp. acted as sole book-running manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 1, 2014. The offering was made by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, via telephone: 212-813-1010, or via e-mail: prospectus@aegiscap.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: GLOBEIMMUNE CONTACT:
         Timothy C. Rodell, M.D.
         Chief Executive Officer and President
         T: 303-625-2820
         information@globeimmune.com

         INVESTOR CONTACT:
         Susan NoonanS.A. Noonan Communications, LLC
         T: 212-966-3650
         susan@sanoonan.com

         MEDIA CONTACTS:
         Lena Evans or Tony Russo, Ph.D.
         Russo Partners LLC
         T: 212-845-4262 or 212-845-4251
         lena.evans@russopartnersllc.comtony.russo@russopartnersllc.com

Source: GlobeImmune, Inc.